Roth Still Positive on Ligand (LGND) Following Promacta sNDA Submission
Tweet Send to a Friend
Roth Capital reaffirms its Buy rating and $92 target on Ligand Pharma (Nasdaq: LGND) following submission of a sNDA to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
